Introduction
============

Differential binding of Fibroblast growth factors (FGFs) to FGF receptor isoforms may confer a high degree of selectivity leading to signaling events that lead to a multitude of specific cellular responses ([@ref-12]; [@ref-33]; [@ref-31]; [@ref-47]). Multiple *Fgf* ligands and three of the *Fgfrs* (*Fgfr1*, *Fgfr2*, and *Fgfr3*) are expressed in the CNS during development, in postnatal stem cell niches such as the dorsal VZ, and in glial lineages ([@ref-16]; [@ref-5]; [@ref-4]; [@ref-9]; [@ref-15]; [@ref-24]; [@ref-3]). This complex system of Fgfs and Fgfrs plays a pivotal role in the normal development, maturation, and function of the central nervous system (CNS) ([@ref-33]; [@ref-59]; [@ref-31]). FGF signaling is implicated in patterning of the CNS, in determining neuronal and glial cell fate, in influencing cerebral cortex size through maintenance of radial glial stem cells, in cerebellar development, and in regional patterning of the neocortex and midbrain-hindbrain boundaries ([@ref-68]; [@ref-21]; [@ref-38]; [@ref-61]; [@ref-55]; [@ref-29]; [@ref-57]; [@ref-60]; [@ref-13]; [@ref-42]; [@ref-36]; [@ref-58]; [@ref-50]; [@ref-43]; [@ref-51]; [@ref-35]; [@ref-56]).

Loss of FGFR1 function by *hGFAP-Cre*-induced deletion of *Fgfr1*^*flox*∕*flox*^ alleles in the dorsal telencephalon of mice results in decreased hippocampal size and volume, with a reduction in the number of dividing progenitor cells of the ventricular zone and DG ([@ref-45]). *Fgfr1* mutants also exhibit a disruption in corpus callosum and hippocampal commissure due to abnormal midline glia development ([@ref-57]; [@ref-63]). The midline glial cells fail to undergo soma translocation and formation of the indusium griseum leading to midline commissural axon guidance defects ([@ref-57]). Furthermore, these mice exhibit postnatal loss of maturation in GABAergic interneurons expressing parvalbumin (PV) and exhibit behavioral hyperactivity ([@ref-42]; [@ref-56]). Hyperactivity and a decrease in number of interneurons in the cortex co-occur in patients with schizophrenia ([@ref-69]; [@ref-1]; [@ref-30]; [@ref-71]). Interestingly, *Fgfr1* expression was found to be increased in the prefrontal cortex of individuals with schizophrenia ([@ref-70]). Dual inactivation of floxed alleles of *Fgfr1* and *Fgfr2* results in abnormal cerebellar morphogenesis including reduced size of the cerebellum due to a defect in proliferation of both cerebellar glia and granule cell precursors, abnormal orientation and morphology of Bergmann glia, and loss of laminar architecture ([@ref-43]). This phenotype is similar to that observed in Fgf9 mutants ([@ref-39]). FGFRs are implicated in maintaining astrocytes in a non-reactive state, and in impeding glial scar formation ([@ref-35]). When *Fgfr1* deletions were targeted to oligodendrocyte lineages, they did not disrupt oligodendrocyte birth, but modulated myelin sheath thickness and remyelination in chronic demyelination models ([@ref-22]; [@ref-23]). Administration of FGF2 into the lateral ventricles has also been shown to increase the number of oligodendrocyte precursor cells in the SVZ ([@ref-3]).

Patients with major depressive disorder (MDD) and bipolar disorder have altered gene expression of FGFs and FGFRs ([@ref-18]; [@ref-25]). *In situ* hybridization revealed that mRNA for *Fgfr1*, and its ligand *Fgf2*, were both down regulated in the hippocampus of rats that had undergone the social defeat paradigm ([@ref-64]). Microinjections of FGF2 into the lateral ventricles of rats resulted in an increase in *Fgfr1* mRNA in the DG within 24 h post FGF2 injections and was accompanied by acute antidepressant-like effects in the force swim test ([@ref-17]). Furthermore, increased anxiety, dysregulation of the hypothalamic pituitary axis and decreased hippocampal glucocorticoid receptor expression is observed in FGF2 knockout mice. These effects are reversible by administration of FGF2 ([@ref-54]). FGF22 and FGF7 are presynaptic organizing molecules that promote differentiation of excitatory and inhibitory presynaptic terminals in the hippocampal cornu ammonis (CA) region 3 through combinatorial signaling of sets of FGFRs ([@ref-67]; [@ref-62]; [@ref-14]). Given the data that FGF2/FGFR1 signaling is important for the regulation of mood and affect, and that FGFR1 signaling may participate in synaptogenesis, a better understanding of the cell types expressing *Fgfr1* is important to improving our understanding of its actions.

Previous estimates of *Fgfr1* expression have been derived from *in situ* hybridization studies and from immunochemistry using antibodies against FGFR1 ([@ref-27]; [@ref-5]; [@ref-4]; [@ref-45]; [@ref-7]), while more recently, molecular studies have identified the timing and or cell specific expression of *Fgfr1* ([@ref-15]; [@ref-24]; [@ref-3]). In embryonic mice, *Fgfr1* is strongly expressed in the hippocampal hem, choroid plexus, cortical ventricular zone, and cortical midline ([@ref-16]; [@ref-4]; [@ref-45]; [@ref-57]). In adult mice, the strongest *Fgfr1* expression is observed in the hippocampus ([@ref-45]). Based on a literature review, [@ref-65] surmised that neuronal populations in the adult hippocampus and cortex mostly express *Fgfr1*, in contrast to other FGF receptors that are considered to be expressed primarily in glia.

Despite clear advances in our understanding of FGF signaling derived from *in situ* hybridization, it suffers from poor cell-type resolution. Likewise, although immunocytochemistry using antibodies raised to FGFR1 has proven to be important, cross-reactivity to other FGFRs remains a concern. To circumvent these issues, we investigated *Fgfr1* expression in PV+ interneurons, employing a transgenic reporter line, *tgFGFR1-EGFPGP338Gsat* bacterial artificial chromosome (BAC), that was obtained from GENSAT, <http://www.gensat.org> ([@ref-56]). In this transgenic line, the gene encoding enhanced green fluorescent protein (*EGFP*) is regulated under the same promoter as *Fgfr1*. Thus, GFP fluorescence should indicate expression of genes encoding *Fgfr1*. We previously showed that in *tgFGFR1-EGFPGP338Gsat mice,* PV+ interneurons did not colocalize with GFP+ cells. Thus, the decrease in PV+ interneurons due to inactivation of *Fgfr1* occurs non-cell-autonomously ([@ref-56]). We also observed that a large number of glia appeared to express *Fgfr1* in adult mice. In the present study, we extend our studies and present a quantitative analysis of the relative expression of *Fgfr1* in neurons versus glial cells during postnatal development of the telencephalon. We show that *Fgfr1* is differentially expressed, primarily in GFAP+ astrocytes and OLIG2+ cells, with a minority of cells colocalizing with NeuN+ neurons. Furthermore, SOX2+ cells, BLBP+ cells and DCX+ cells in the cortex, hippocampus, subventricular zone (SVZ), and hypothalamus of mice are colocalized with the GFP signal, indicating that these cells also express *Fgfr1*.

Methods and Materials
=====================

Animals
-------

Wild type Swiss Webster mice were crossed with mice expressing enhanced green fluorescent protein (EGFP) under the same promoter as *Fgfr1* (*tgFGR1-EGFPGP338Gsat*). The transgenic line, *tgFGR1-EGFPGP338Gsat* was generated from the GENSAT project (GENSAT.org) by microinjecting bacterial artificial chromosome with *Fgfr1* promoter driving EGFP into the pronucleus of fertilized mouse eggs. GENSAT produces transgenic BAC-EGFP reporter and BAC-Cre recombinase driver mouse lines with the aim to map the expression of genes in the CNS of mice ([@ref-32]). This line was obtained from the Mutant Mouse Resource Center (MMRRC.org) at UC Davis. This study was conducted in an ethical manner, utilizing the recommendations of The Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animals were euthanized under the University of Louisiana at Lafayette IACUC committee APS numbers 2012-8717-046, 2013- 8717-053, 2014-8717 040, 2015-8717-033. Tissue collected for this study was performed under ketamine/xylazine cocktail for P7 and older animals.

Genotyping
----------

The mice were genotyped by polymerase chain reaction (PCR) for GFP and through GFP screening with goggles containing a GFP filter (BLS LTD). For PCR based genotyping, tails of mice were collected and DNA was extracted from the tail using 50 mM sodium hydroxide (95 °C for 30 min), followed by neutralization with 1M TRIS (pH 7.6). Master mix for 1 reaction of PCR for amplifying *GFP* was created using 2.5 µl of 10× PCR buffer, 0.5 µl of 10 mM dNTP mix, 1 µl of eGFP forward and reverse primer mix (Forward: AAGTTCATCTGCACCACCG and Reverse: TGCTCAGGTAGTGGTTGTCG), 0.2 µl of 5 units/µl Hot start Taq Polymerase and 18.8 µl of distilled water. Two microliters of DNA sample were added to 23 μl of Master mix per PCR tube and the samples were amplified in the Applied Biosystems 96 Well Thermocycler. In adult *tgFGR1-EGFPGP338Gsat* positive mice, we found we could reliably genotype mice due to GFP expression in the eye, using GFP goggles (available from BLS).

Immunostaining
--------------

P7 mice were anesthetized with ketamine/xylazine (100 mg and 10 mg per kg of body weight respectively) and euthanized by cervical dislocation. Brains were dissected out and in 4% PFA overnight. Adult mice were euthanized by cardiac perfusion under deep anesthesia (ketamine/xylazine as above). Mice were perfused with cold 1× Phosphate Buffered Saline (PBS) followed by 4% PFA in 1× PBS. Brains were post fixed overnight and cryoprotected as described above. Brains collected from P7 and one month ages were cryoprotected in 20% sucrose/1xPBS, and cryopreserved with exposure to dry ice and embedded in optimal cutting temperature (OCT) at the time of sectioning. The tissue was thick sectioned (50 µm, free floating) in a cryostat (Microm, HM 505 E) in a series of 10 vials containing 1xPBS. Samples were stored in PBS with 0.2% sodium azide at 4 °C, and protected from light exposure.

Prior to antibody incubation, sections were blocked with 10% serum in PBS with 0.2% triton × (Sigma Aldrich) and 0.1% tween 20 (Sigma Aldrich), except for anti-Gad67 staining which did not include detergents. Primary antibodies ([Table 1](#table-1){ref-type="table"}) were detected with Alexa conjugated secondary antibodies (Jackson labs and Abcam) or AMCA conjugated secondary antibodies (Vector) in 5% serum. VECTASHIELD DAPI was used for double staining and VECTASHIELD without DAPI was used for triple staining when mounting sectioned tissue onto polyprep slides.
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###### Antibodies used for immunofluorescence detection.
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  Antigen        Raised in   Dilution   Source            Marker of
  -------------- ----------- ---------- ----------------- --------------------
  NeuN           Mouse       1:125      Millipore         Neuron
  GFAP           Rabbit      1:500      Dako Cytomation   Astrocyte
  GFP            Chicken     1:250      Abcam Inc.        GFP
  Sox2           Rabbit      1:250      Millipore         Neuronal precursor
  Olig2          Mouse       1:1000     Millipore         Oligodendrocyte
  DCX            Mouse       1:250      Abcam Inc.        Neuroblast
  GAD67          Mouse       1:1000     Millipore         Inhibitory neuron
  Calretinin     Rabbit      1:1000     Millipore         Inhibitory neuron
  Somatostatin   Rat         1:200      Millipore         Inhibitory neuron
  BLBP           Rabbit      1:1000     Abcam Inc.        Stem cells

Cell Counting
-------------

Unbiased estimated counts of astrocytes expressing glial fibrillary acidic protein (GFAP), neurons expressing NeuN, and oligodendrocytes and oligodendrocyte precursors expressing Olig2 were obtained using StereoInvestigator software (Microbrightfield, MBF) coupled with an AxioCam MRm on the Zeiss axioimager microscope equipped with an ApoTome.2. The Optical Fractionator probe on Stereoinvestigator was employed, with tops of cells counted in three-dimensional counting boxes, which were set to specific parameters ([Table 2](#table-2){ref-type="table"}). For counts of the cortex and hippocampus, 50 µm sections were sampled every 20th (cortex) and every 10th section (Hippocampus). The CA1, CA2, and CA3 regions were counted together and included the stratum lacunosum, stratum radiatum, stratum pyramidale and the stratum oriens. The DG was counted separately. For the cortex, at these ages, the expression of GFP seemed fairly ubiquitous and so the cortex was counted in its entirety using stereology as outlined above and in [Table 2](#table-2){ref-type="table"}. Fluorescence images were acquired through StereoInvestigator imaging software. Of note, cell counts indicated that presence of the GFP transgene did not cause cell lethality in cortical or hippocampal cells. For P7 counts, 3 animals per genotype were counted for NeuN, GFAP, and Olig2 (same animals for all 3 counts). For 1 month old animals, 3 animals per group were counted for cortex and CA, and 4 animals in the GFP+ group for the DG. The GFAP/NeuN/GFP counts were determined from triple stained samples. The Olig2 counts were from 3 animals per group.
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###### Parameters used for stereological cell counts.
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  Time point   Area     Counting frame (µm)   Grid size (µm)   Dissector height (µm)   Guard zone height (µm)   Section thickness (µm)
  ------------ -------- --------------------- ---------------- ----------------------- ------------------------ ------------------------
  P7           Cortex   75 × 75               650 × 700        15                      1                        50
               DG       75 × 75               250 × 250        15                      1                        50
               CA       75 × 75               500 × 500        15                      1                        50
  1 month      Cortex   75 × 75               1,000 × 1,000    15                      1                        50
               DG       75 × 75               275 × 200        15                      1                        50
               CA       75 × 75               350 × 250        15                      1                        50

To determine the percentage of GFP+ cells that were neuronal stem cells expressing Sox2 and neuroblasts expressing DCX (3 animals per group), we acquired *z* stack images of the anterior DG hemisphere and a section 500 µm posterior to this first section. The *z* stack images obtained to count SOX2 markers were 19 µm thick with each slice 1 µm thick from 3 GFP+ mice and 2 for the control mice). The *z* stack images acquired to count DCX markers were 10 µm thick with each slice 1 µm thick (3 animals per group).

Statistical analysis
--------------------

Data from the StereoInvestigator software were entered into Excel, imported to JMP Pro 11, and analyzed by student *t*-tests, or ANOVA, using SAS.

Results
=======

*Fgfr1* is expressed in various cells types of the dentate gyrus, CA, and subventricular zone (SVZ) at P7
---------------------------------------------------------------------------------------------------------

Previous *in situ* studies indicated high levels of *Fgfr1* mRNA in the hippocampus, including DG and CA regions. To investigate the cell types expressing *Fgfr1* in the hippocampus of P7 control and *tgfgfr1-EGFP*+ mice, samples were stained by immunocytochemistry for cell-type markers to identify each of the following: GFAP+ stem cells and astrocytes, NeuN+ neurons, BLBP+ stem cells, and DCX+ neuroblasts. We also used an anti GFP antibody to ensure detection of GFP in fixed tissue. However, *Gfp* expression is visible without amplification, especially in the hippocampus and subventricular zone. The cell-type marker staining (red fluorescence) was imaged alongside GFP immunostaining (green fluorescence) to reveal which cell types express *Fgfr1* and with DAPI counterstaining (blue fluorescence) to image nuclei ([Fig. 1](#fig-1){ref-type="fig"}). The colocalization of a cell type marker and *Fgfr1* expression is indicated by yellow fluorescence caused by overlapping red and green fluorescence. GFAP and GFP immunostaining showed GFP+ cells in the GFAP+ stem cells of the subgranular zone (SGZ) of the DG of *tgfgfr1-EGFP*+ mice ([Figs. 1A](#fig-1){ref-type="fig"}--[1C](#fig-1){ref-type="fig"}, [Fig. S1](#supp-1){ref-type="supplementary-material"}, and <https://figshare.com/s/36bc336d5b0ccb95efe8>) with little to no green fluorescence in GFP-controls ([Figs. 1D](#fig-1){ref-type="fig"}--[1F](#fig-1){ref-type="fig"}). In the CA region of the hippocampus, GFAP+/GFP+ cells were primarily observed surrounding the stratum pyramidale, in the stratum radiatum, stratum oriens, as well as the white matter above the CA region ([Figs. 1G](#fig-1){ref-type="fig"}--[1I](#fig-1){ref-type="fig"}, [Fig. S1](#supp-1){ref-type="supplementary-material"}) with little to no green fluorescence in GFP-littermate controls ([Figs. 1J](#fig-1){ref-type="fig"}--[1L](#fig-1){ref-type="fig"}). There was strong GFP fluorescence in the stratum pyramidale of the CA region. This GFP staining colocalized with NeuN+ cells (neurons) ([Figs. 2A](#fig-2){ref-type="fig"}--[2C](#fig-2){ref-type="fig"}, [Fig. S2](#supp-2){ref-type="supplementary-material"}) with little to no green fluorescence in GFP-littermate controls ([Figs. 2D](#fig-2){ref-type="fig"}--[2F](#fig-2){ref-type="fig"}). NeuN+/GFP+ cells were also observed in some, but not all, granule cell layer neurons of the developing DG of *tgfgfr1-EGFP*+ mice ([Figs. 2G](#fig-2){ref-type="fig"}--[2I](#fig-2){ref-type="fig"}) with little to no green fluorescence in GFP-controls ([Figs. 2J](#fig-2){ref-type="fig"}--[2L](#fig-2){ref-type="fig"}). Stereological analysis of *tgfgfr1-EGFP* expression in GFAP+ cells of the DG showed that of GFP+ cells, 24% ± 8% are GFAP positive, and of GFAP+ cells, 50% ± 8% are GFP+. Of GFP+ cells in the CA, 50% ± 5% are GFAP positive and of GFAP+ cells in the CA, 43% ± 9% are GFP positive ([Table 3](#table-3){ref-type="table"}). One-way ANOVA statistical analysis revealed that the total number of GFAP+ cells in the DG and CA of *tgfgfr1-EGFP*+ are not significantly different from their littermate controls ([Table 3](#table-3){ref-type="table"}).

![*Fgfr1* expression in GFAP+ cells of the hippocampus at P7.\
GFAP (A, D) GFP (B, E) immunostaining of the DG in P7 *tgfgfr1-EGFP*+ mice (A--C, *n* = 3) and *tgfgfr1-EGFP-*littermate controls (D--F, *n* = 3) demonstrated strong GFAP/GFP colocalization in cells of the SGZ (arrowheads) and their radial fibers into the GCL (small arrows). GFAP and GFP immunostaining of the CA region in *tgfgfr1-EGFP*+ mice (G--I, *n* = 3) and *tgfgfr1-EGFP*-controls (J--L, *n* = 3). GFP+ staining was observed in stratum pyramidale (SP) as well as in cells above (stratum oriens, SO) and below (stratum radiatum, SR) this layer (H). GFAP+/GFP+ colabeling (arrowheads) was observed in primarily in the SO and SR within the CA region, and in the white matter dorsal to the hippocampus. Scale bar is 25 µm. SGZ, subgranular zone; GCL, granule cell layer; SP, stratum pyramidale.](peerj-05-3173-g001){#fig-1}

![*Fgfr1* expression in NeuN+ cells of the hippocampus at P7.\
NeuN (A, D) and GFP (B, E) immunostaining of the CA region in *tgfgfr1-EGFP*+ mice (A--C, *n* = 3) and *tgfgfr1-EGFP-*controls (D--F, *n* = 3). Neun+/GFP+ staining was observed in stratum pyramidale (SP) of the CA region. NeuN (G, J) and GFP (H, K) immunostaining of the DG in *tgfgfr1-EGFP*+ mice (G--I, *n* = 3) and *tgfgfr1-EGFP-*controls (J--L, *n* = 3). There was some colabeling in the granule cell layer between GFP+ and NeuN+ cells. Scale bar is 25 µm in A--D and 50 µm in G--L.](peerj-05-3173-g002){#fig-2}
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###### Stereology Results for Hippocampal DG, CA, and Cortex.
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  Age       Area     Marker   \# of Marker+ cells   *P*-value   \# of GFP+ cells      \% of GFP+ cells expressing Marker   \% of Marker+ cells expressing GFP
  --------- -------- -------- --------------------- ----------- --------------------- ------------------------------------ ------------------------------------
  P7        DG       GFAP     5614 ± 467            0.37        15,974 ± 7447         24% ± 8%                             50% ± 8%
            CA       GFAP     51,258 ± 1741         0.42        46,413 ± 14,851       50% ± 5%                             43% ± 9%
            Cortex   GFAP     41,2147 ± 22,494      0.25        12,20518 ± 53,849     32% ± 4%                             93% ± 2%
  1 Month   DG       NeuN     75,5542 ± 22,8698     0.52        24,3542 ± 12,945      16% ± 6%                             5% ± 0.7%
                     GFAP     14,9161 ± 22,540      0.53        24,3542 ± 12,945      51% ± 3%                             85% ± 4%
            CA       NeuN     67,0709 ± 59,607      0.27        37,9768 ± 27,634      25% ± 7%                             15% ± 6%
                     GFAP     28,6614 ± 39,645      0.86        37,9768 ± 27,634      61% ± 9%                             81% ± 3%
            Cortex   GFAP     17,77872 ± 87,6236    0.66        23,21696 ± 10,56829   57% ± 7%                             83% ± 6%
                     NeuN     49,62422 ± 22,64757   0.97        23,21696 ± 10,56829   25% ± 4%                             12% ± 2%
                     Olig2    80,0755 ± 13,7359     0.85        15,74962 ± 19,5563    29% ± 0.9%                           58% ± 0.08%

We further explored *Fgfr1* promoter driven expression of *Gfp* in the postnatal neurogenic niches of the DG and SVZ of the lateral ventricles at P7. Immunostaining for DCX (neuroblasts) and GFP extensively colocalized in the SGZ and granule cell layer (GCL) of the DG ([Figs. 3A](#fig-3){ref-type="fig"} and [3B](#fig-3){ref-type="fig"}, low and high magnification respectively) with nearly all DCX positive cells co-expressing GFP. Postnatally, the SVZ of the lateral ventricles gives rise to olfactory bulb neurons, astrocytes and oligodendrocytes ([@ref-11]). The kind of olfactory bulb neuron generated depends on the location of the stem cell within the VZ ([@ref-20]; [@ref-11]). GFP+ cells were observed in the SVZ, consistent with previous studies of postnatal *Fgfr1* expression ([@ref-19]). However, DCX did not colocalize with GFP staining in the SVZ of the lateral ventricles ([Fig. 3C](#fig-3){ref-type="fig"}), in contrast to what was observed in the DG of the hippocampus. This difference is likely reflective of the differences in cell type generated, granule cell neurons that are projection neurons in the SGZ and largely interneurons in the SVZ. Immunostaining with BLBP (stem cells) and GFP antibodies revealed colocalization of *Fgfr1* driven GFP in the subgranular zone (SGZ) of the DG ([Figs. 3D](#fig-3){ref-type="fig"} and [3E](#fig-3){ref-type="fig"}, low and high magnification, respectively) as well as BLBP+ cells of the SVZ ([Figs. 3F](#fig-3){ref-type="fig"} and [3G](#fig-3){ref-type="fig"}).

![*Fgfr1* expression in neuroblasts of the hippocampus, and stem cells of the hippocampus and SVZ at P7.\
DCX and GFP colocalize in neuroblasts of the P7 mice in the granule cell layer of the DG in the hippocampus (A, low magnification, and B, high magnification), but not in the SVZ of the lateral ventricles (C). Many of the BLBP+ cells colocalize with GFP in the stem cells of the SGZ of the DG (D, low magnification, and E, high magnification), as well as stem cells in the SVZ (F, G). Scale bar is 50 µm in A, C, D, F and 25 µm in B and E, and 12.5 µm in G. Arrows indicate examples of double labeled cells, dashed lines denote SVZ.](peerj-05-3173-g003){#fig-3}

*Fgfr1* is expressed in cortical GFAP+ astrocytes and NeuN+ neurons at P7
-------------------------------------------------------------------------

To determine which cortical cells express *Fgfr1*, we stained the cortical tissue of P7 *tgfgfr1-EGFP*+ and control mice with GFAP and NeuN antibodies. Whereas GFP+ cells colocalized with GFAP+ astrocytes throughout the cortex ([Figs. 4A](#fig-4){ref-type="fig"}--[4C](#fig-4){ref-type="fig"}), GFP+ cells colocalized with NeuN+ cells (neurons) mostly in layers 5 and 6 of the cortex at this age ([Figs. 4D](#fig-4){ref-type="fig"}--[4F](#fig-4){ref-type="fig"}). Stereological analysis of the cortex region revealed that of GFP+ cells in the cortex, 32% ± 4% are GFAP positive. Of the cortical GFAP+ cells, 93% ± 2% are GFP positive. This analysis indicates that most *Gfap* expressing astrocytes also express *Fgfr1*. The total number of cortical GFAP+ cells of *tgfgfr1-EGFP*+ mice was not significantly different from the number of cells in littermate controls ([Table 3](#table-3){ref-type="table"}), suggesting that the insertion of the transgene does not significantly alter the number of astrocytes expressing *Gfap*.

![*Fgfr1* expression in cortex of P7 mice.\
Cortical GFAP, NeuN, BLBP and GFP immunostaining in P7 *tgfgfr1-EGFP*+ mice (A, B, D, E, G--J, *n* = 3) and *tgfgfr1-EGFP-*controls (C, F, *n* = 3). GFP+ cells colocalize with GFAP+ cells (A, B). GFP+ cells weakly colocalize with NeuN+ at layers 5 and 6 of the cortex (D, E, dashed line separates cortical plate and subcortical white matter). GFP+ cells colocalize with Olig2+ cells in the cortex (G--I) and some of the OLIG2+ cells of the subcortical white matter and SVZ (J). GFP+ cells colocalize with BLBP+ cells throughout the layers of the cortex (K--M) as well as the BLBP+ cells and Bergmann glia of the cerebellum (N). Scale bar is 50 µm. 1, 2, 3, 4, 5, 6, layers of the cortex. Arrows indicate examples of double labeled cells.](peerj-05-3173-g004){#fig-4}

We examined whether *tgfgfr1-EGFP*+ was expressed in oligodendrocytes and their precursors by staining for OLIG2 in the cortex. We found that OLIG2+ staining colocalized with GFP in the cortex ([Figs. 4G](#fig-4){ref-type="fig"}--[4I](#fig-4){ref-type="fig"}). We also found sparse colabeling of OLIG2+ cells in the SVZ and subcortical white matter ([Fig. 4J](#fig-4){ref-type="fig"}). GFP expression within these cells appears to be lower than that of surrounding cells, and may reflect residual GFP expression once progenitor cells that express *Fgfr1* have divided and an oligodendrocyte has initiated differentiation to a more mature subtype. At P7, radial glia of the cortex are undergoing soma translocation to become astrocytes, and can be detected with BLBP. BLBP and GFP immunostaining revealed strong colocalization throughout the cortex ([Figs. 4K](#fig-4){ref-type="fig"}--[4M](#fig-4){ref-type="fig"}). At P7, GFP staining colocalized with BLBP+ stem cells and Bergmann Glia in the developing cerebellum ([Fig. 4N](#fig-4){ref-type="fig"}). This finding is consistent with the participation of FGFR1/FGFR2 signaling in Bergmann Glia morphology and cerebellar development ([@ref-43]). Furthermore, GFP+ cells colocalized with GFAP+ astrocytes of the cerebellum, but not within granule cell layer or molecular layer neurons that stain with NeuN. GFP+ cells likely colocalized with NeuN-Purkinje neurons based on the location and size of GFP+ cells in the Purkinje layer ([Fig. S3](#supp-3){ref-type="supplementary-material"} and <https://figshare.com/s/722ecee87a3f32427759>). While counts were not obtained from regions such as the striatum or the thalamus, we observed GFAP colocalization with GFP in multiple areas of the brain, and this seemed to be a general feature of GFAP positive cells.

*Fgfr1* is expressed in specific cell types of the hippocampus and SVZ at 1 month
---------------------------------------------------------------------------------

We next investigated *Fgfr1* expression in 1-month *tgfgfr1-EGFP*+ mice. Immunostaining for SOX2+ cells (stem cells), DCX+ cells (neuroblasts), NeuN+ neurons, GFAP+ astrocytes and stem cells, and OLIG2+ oligodendrocytes was performed in combination with GFP immunostaining to determine which cell types express *Fgfr1* in the DG and CA of the hippocampus, as well as the SVZ. GFP+ cells colocalized with SOX2+ cells ([Figs. 5A](#fig-5){ref-type="fig"}--[5E](#fig-5){ref-type="fig"}, [Figs. S4A](#supp-4){ref-type="supplementary-material"} and [S4B](#supp-4){ref-type="supplementary-material"}) and DCX+ cells ([Figs. 5F](#fig-5){ref-type="fig"}--[5J](#fig-5){ref-type="fig"}, [Figs. S4C](#supp-4){ref-type="supplementary-material"} and [S4D](#supp-4){ref-type="supplementary-material"}) in the SGZ and granule cell layers. To determine the percentage of GFP+ cells that were SOX-2 positive and DCX positive, we obtained *z* stack images of an anterior dentate gyrus hemisphere and posterior dentate gyrus hemisphere, and performed counts from these images. Of the GFP+ cells counted in the *z* stack, 33% ± 2% are SOX2 positive. Conversely, the majority of SOX2+ cells, 71% ± 2%, are GFP positive ([Fig. 5E](#fig-5){ref-type="fig"}). Of the GFP+ cells counted in the *z* stack, 64% ± 0.9% are DCX positive and of DCX+ cells, 86% ± 2% are GFP positive ([Fig. 5J](#fig-5){ref-type="fig"}). Triple staining with GFP, GFAP and NeuN antibodies revealed that GFAP+ cells (stem cells) and NeuN+ cells (neurons) colocalized with GFP+ cells in the SGZ ([Figs. 5K](#fig-5){ref-type="fig"}--[5N](#fig-5){ref-type="fig"}, [Fig. S4E](#supp-4){ref-type="supplementary-material"}) and in the CA region ([Figs. 5O](#fig-5){ref-type="fig"}--[5R](#fig-5){ref-type="fig"} and [Fig. S4F](#supp-4){ref-type="supplementary-material"}), respectively. GFP+ cells did not colocalize with OLIG2+ cells (oligodendrocytes) in the DG ([Fig. S5](#supp-5){ref-type="supplementary-material"}). Taken together, these results indicate that GFP (*Fgfr1*) was expressed in stem cells and neuroblasts of the DG. Stereological analysis of *tgfgfr1-EGFP* expression in NeuN+ cells of the DG showed that of GFP+ cells, 16% ± 6% are NeuN positive and of NeuN+ cells, 5% ± 0.7% are GFP positive. Of GFP+ cells in the CA, 25% ± 7% are NeuN positive and of NeuN+ cells, 15% ± 6% are GFP positive. Stereological analysis of *tgfgfr1-EGFP* expression in GFAP+ cells of the DG showed that of GFP+ cells, 51% ± 3% are GFAP positive and of GFAP+ cells, 85% ± 4% are GFP positive. Of GFP+ cells in the CA, 61% ± 9% are GFAP positive and of GFAP+ cells, 81% ± 3% are GFP positive. These findings indicate that most GFAP positive astrocytes express *Fgfr1* at 1 month. The total number of SOX2+ cells, DCX+ cells, NeuN+ cells and GFAP+ cells of *tgfgfr1-EGFP*+ mice were not significantly different from their littermate controls in the DG and CA (Sox2: *p* = 0.23, DCX: *p* = 0.88 and [Table 3](#table-3){ref-type="table"}).

![*Fgfr1* expression in the dentate gyrus and CA of 1-month mice.\
A majority of SOX2+ cells (A, C) in the DG of *tgfgfr1-EGFP*+ mice colocalize with GFP (B, C, arrows indicate examples of double labeled cells) compared to GFP- controls (D). Counts of SOX2+ and GFP+ cells were made directly from *Z* stack images (19 µm thick, 1 µm steps, from *Z* stack images using StereoInvestigator software from MBF). The relative proportions of single, and double-labeled cells in the DG were quantified (E), with 71% of SOX2 positive cells expressing GFP. A majority of DCX+ (F, H) cells in the DG also express GFP (G, H, arrows indicate examples of double labeled cells) compared to GFP-controls (I). Counts for DCX+ and GFP+ were performed on 10 µm thick, 1 µM step size, *Z* stack images using Image J (*n* = 3) of the dentate gyrus. The relative proportions of single, and double-labeled cells in the DG were quantified (J) with 85% of DCX+ cells expressing GFP. GFAP (Red), NeuN (Blue), and GFP triple immunolabeling was perfused on 1-month old mice. We observed GFAP and GFP colabeling in both the SGZ of the DG (K--N, arrows), as well as in the CA region (O--R) where most GFAP+ cells are present in the stratum oriens or stratum radiatum. NeuN+/GFP+ double positive cells were primarily observed in the stratum pyramidale (SP) of the CA region in the hippocampus (double arrows). These cells were quantified by unbiased stereology with the StereoInvestigator ([Table 3](#table-3){ref-type="table"}). Scale bar in I is 25 µm for images A--D and F--I, Scale bar in R is 50 µm for images K--R. Arrows indicate examples of double labeled cells.](peerj-05-3173-g005){#fig-5}

Many GFAP+ cells also express GFP in the SVZ ([Figs. 6A](#fig-6){ref-type="fig"}--[6H](#fig-6){ref-type="fig"}) of 1 month *tgfgfr1-EGFP*+ mice. Colocalized GFP positive cells and GFAP positive fibers were observed both within the SVZ and in the white matter above it ([Figs. 6D](#fig-6){ref-type="fig"}, [6G](#fig-6){ref-type="fig"} and [6H](#fig-6){ref-type="fig"}). There was also significant colocalization of GFP with SOX2+ cells ([Figs. 6I](#fig-6){ref-type="fig"}--[6L](#fig-6){ref-type="fig"}) indicating that GFAP+ and SOX2+ stem cells of the SVZ express *Fgfr1*. Similar to what was found at P7, GFP+ cells did not colocalize with DCX+ cells (neuroblasts) in the SVZ ([Figs. 6M](#fig-6){ref-type="fig"}--[6O](#fig-6){ref-type="fig"}) or in the DCX+ cells of rostral migratory stream (RMS) as it enters the olfactory bulb ([Fig. 6P](#fig-6){ref-type="fig"}). In the rostral migratory stream, GFP staining surrounds the DCX+ cells as would be expected from astrocytes surrounding the migrating neuroblasts.

![*Fgfr1* expression in the SVZ and rostral migratory stream of 1-month mice.\
GFP (A, E, D, H), GFAP (B, F, G, H), NeuN (C, D), immunostaining of the SVZ in 1-month *tgfgfr1-EGFP*+ mice (A--H, *n* = 3). GFP+ cells of the SVZ colocalized with GFAP+ cells (D, and G, H. Arrowheads in E--H = GFAP/GFP+ cells and GFAP+ fibers. GFP (I, K, L) and SOX2 (J, K, L) staining demonstrated that many, but not all SOX2+ cells also colabel with GFP+ (K and L, arrows indicate double labeled cells, DAPI staining included in L). In contrast, DCX+ neuroblasts in the SVZ and rostral migratory stream did not colabel with GFP (M--P). Scale bar is 50 µm in A--D and M--P and 25 µm in E--L. Dashed lines indicated SVZ region examined.](peerj-05-3173-g006){#fig-6}

*Fgfr1* is expressed in cortical GFAP+ astrocytes, NeuN+ neurons and OLIG2+ cells at 1 month
--------------------------------------------------------------------------------------------

To determine which cortical cells express *Fgfr1*, we examined cortical tissue of 1-month old *tgfgfr1-EGFP*+ and control mice immuonostained with GFAP, NeuN or OLIG2 antibodies alongside GFP antibodies. Analysis of *Fgfr1* expression in the cortex revealed that GFP+ cells colocalized with GFAP+ and NeuN+ cells ([Figs. 7A](#fig-7){ref-type="fig"}--[7E](#fig-7){ref-type="fig"}, compared to control [7F](#fig-7){ref-type="fig"}). Of note, GFP immunofluorescence appeared less brightly fluorescent in cells colocalizing with NeuN compared to those colocalizing with GFAP. GFP+ cells also colocalized with OLIG2+ cells ([Figs. 7G](#fig-7){ref-type="fig"}--[7H](#fig-7){ref-type="fig"}) with little to no green fluorescence occurring in littermate controls ([Fig. 7I](#fig-7){ref-type="fig"}). Stereological analysis of the cortex revealed that of GFP+ cells, 57% ± 7% are GFAP positive. Of the GFAP+ astrocytes, 83% ± 6% are GFP positive. Of GFP+ cells, 25% ± 4% are NeuN positive and of NeuN+ cells, 12% ± 2% are GFP positive. Of GFP+ cells, 29% ± 0.9% are OLIG2 positive and of OLIG2+ cells, 58% ± 0.08% are GFP positive. The total number of cortical GFAP+, NeuN+, and OLIG2+ cells of *tgfgfr1-EGFP*+ mice were not significantly different from their littermate controls ([Table 3](#table-3){ref-type="table"}).

![*Fgfr1* expression in the cortex of 1-month mice.\
Cortical GFAP (Red), NeuN (Blue), and GFP immunostaining in 1-month *tgfgfr1-EGFP*+ mice (A--E, *n* = 3) and control *tgfgfr1-EGF*-mice (F, *n* = 3). GFP+ cells colocalized with GFAP+ (arrows) (A, B, merged in D, low magnification in E), and some NeuN+ (double arrows) (B, C, merged in D, lower magnification in E). Immunostaining for Olig2+ in *tgfgfr1-EGFP*+ mice (G, H, Red, Olig2; Blue, DAPI) compared to *tgfgfr1-EGF-*mice (I) demonstrated that many Olig2+ cells colocalized with GFP. DAPI staining omitted from low magnification pictures in G and I. Scale bars are 50 µm. Dashed line denotes top of cortex.](peerj-05-3173-g007){#fig-7}

*Fgfr1* is expressed in various cell types of the hypothalamus at P7 and 1 month
--------------------------------------------------------------------------------

Comparing *Fgfr1* expression in different regions of the P7 and 1-month old mice, we observed GFP expression in cells of the hypothalamus and among cells lining the third ventricle, within the arcuate nucleus and median eminence ([Fig. 8](#fig-8){ref-type="fig"}, [Fig. S6](#supp-6){ref-type="supplementary-material"} and <https://figshare.com/s/f17d6889939bd680152d>). Compared to the control hypothalamus ([Figs. 8A](#fig-8){ref-type="fig"}--[8C](#fig-8){ref-type="fig"}), GFP+ cells strongly colocalized with SOX2+ cells throughout the hypothalamus and third ventricle and arcuate nucleus ([Figs. 8D](#fig-8){ref-type="fig"}--[8I](#fig-8){ref-type="fig"}) in 1-month *tgfgfr1-EGFP*+ mice. GFAP+ tanycytes, including those of the arcuate nucleus were among the hypothalamic cells observed to express *Fgfr1* both at 1 month and at P7 ([Figs. 8J](#fig-8){ref-type="fig"}--[8L](#fig-8){ref-type="fig"}). Tanycytes participate in neuroendocrine regulation and transport of molecules from the CSF to the hypothalamus, release of gonadotropin-releasing hormone, and production of triiodothyronine (T3) in the brain ([@ref-53]). GFP expression was not observed in NeuN+ or OLIG2+ cells of the hypothalamus ([Figs. 8M](#fig-8){ref-type="fig"}--[8O](#fig-8){ref-type="fig"}, [Figs. S6A](#supp-6){ref-type="supplementary-material"}--[S6D](#supp-6){ref-type="supplementary-material"}). At P7, we also observed colocalization of BLBP and GFP in the hypothalamus near the third ventricle, but not many in the median eminence ([Figs. S6E](#supp-6){ref-type="supplementary-material"} and [S6F](#supp-6){ref-type="supplementary-material"}, <https://figshare.com/s/f17d6889939bd680152d>).

![*Fgfr1* expression in the hypothalamus.\
SOX2+ positive cells were observed along the third ventricle of *tgfgfr1-EGF-*control mice (A--C) and *tgfgfr1-EGF*+ mice (D--I). These SOX2+ cells also express GFP under the *Fgfr1* promoter (D--I). GFAP+ tanacytes along the third ventricle and arcuate nucleus also colocalize with GFP, as do GFAP+ cells within the hypothalamus (J--L). NeuN+ cells in the hypothalamus do not colocalize with GFP (M--O). A--L, 1 month; M--O, P7. Scale bar is 50 µm.](peerj-05-3173-g008){#fig-8}

Calretinin (CR) and somatostatin (SST) neurons express *Fgfr1* in one-month old mice
------------------------------------------------------------------------------------

The NeuN+/GFP+ neurons observed at 1 month were not restricted to any specific cortical layer, and a minority population of GFP colocalized with NeuN+ neurons. We therefore sought to determine if inhibitory neurons express *Fgfr1*. Tissue from one-month old *tgfgfr1-EGFP*+ mice ([Figs. 9B](#fig-9){ref-type="fig"}--[9C](#fig-9){ref-type="fig"}) and their control littermates ([Fig. 9A](#fig-9){ref-type="fig"}) was stained for GAD67. Some GAD67+ cells colocalized with GFP in the cortex ([Fig. 9B](#fig-9){ref-type="fig"}), but not in the hippocampus ([Fig. 9C](#fig-9){ref-type="fig"}) or SVZ ([Fig. 9D](#fig-9){ref-type="fig"}). Our previous investigations determined that GFP was not colocalized with PV+ interneurons ([@ref-56]). This led to the experiments in which staining the one-month old tissue with calretinin (CR) and somatostatin (SST) was performed alongside GFP immunostaining. CR+ inhibitory neurons express GFP in the cortex ([Figs. 9E](#fig-9){ref-type="fig"} and [9F](#fig-9){ref-type="fig"}), DG ([Fig. 9G](#fig-9){ref-type="fig"}), and SVZ ([Fig. 9H](#fig-9){ref-type="fig"}). Some SST+ inhibitory neurons express GFP in the anterior cingulate of the cortex ([Figs. 9I](#fig-9){ref-type="fig"} and [9J](#fig-9){ref-type="fig"}), but none were observed in the DG ([Fig. 9K](#fig-9){ref-type="fig"}).

![*Fgfr1* expression in the 1-month interneurons.\
GAD67, CR, SST, and GFP immunostaining of the cortex, DG, and SVZ in one-month old *tgfgfr1-EGFP-*controls (A, E, I, *n* = 2 SST, *n* = 3 GAD67, CR) and *tgfgfr1-EGFP*+ mice (B--D, F--H, J, K, *n* = 2 SST, *n* = 3 GAD67, CR). GFP+ cells colocalized with GAD67+ cells in the cortex (B, arrows), but not in the DG (C) and SVZ (D). Some CR+ cells express GFP in the cortex (F), DG (G) and SVZ (H). Some SST+ cells express GFP in the anterior cingulate of the cortex (J), but not in the DG (K). Scale bars are 50 µm. Dashed lines indicate SVZ, AC, anterior cingulate. Arrows denote double labeled cells.](peerj-05-3173-g009){#fig-9}

Discussion
==========

Through immunostaining for GFP in *tgFgfr1-EGFP*+ mice of the *tgFGFR1-EGFPGP338Gsat* line, we examined the cell specific expression of *Fgfr1* in the cortex, hippocampus, SVZ, hypothalamus, and cerebellum from P7 to one-month of age. In postnatal brains, *Fgfr1* is highly expressed in the hippocampus, SVZ, hypothalamus, and in numerous cells of the cortex. In the hippocampus, *Fgfr1* was expressed in DCX+ neuroblasts, in GFAP+ stem cells and astrocytes, and Sox2+ stem cells of the SGZ, and in neurons of the CA. Furthermore, *Fgfr1* was expressed in astrocytes, neurons, and oligodendrocyte lineages. *Fgfr1* expression in cortical neurons was not restricted to a single layer and colocalized with CR+ and SST+ inhibitory neurons. *Fgfr1* expression was also observed in Bergmann glia and GFAP+ astrocytes of the cerebellum.

The *tgFgfr1-EGFP*+ line has been shown to be a robust model in identifying which cell types express *Fgfr1*, corroborating the findings of previous *in situ* hybridization studies ([@ref-16]; [@ref-27]; [@ref-5]; [@ref-4]; [@ref-45]) and more modern molecular profiling studies ([@ref-41]; [@ref-9]; [@ref-15]; [@ref-3]). This transgenic line gives the added benefit of allowing simple identification of the subtype of cells expressing *Fgfr1* by immunofluorescence staining, since GFP is regulated by the *Fgfr1* promoter. Unlike the use of antibodies for FGFR1, which may have cross reactivity with similar FGFR family members, we can have greater confidence that we are identifying *Fgfr1* expression accurately within a cell.

Previous studies have shown that inactivation of FGFR1/FGFR2 and FGFR1/FGFR2/ FGFR3 signaling in the developing dorsal VZ results in premature depletion of radial glial stem cells and a smaller cortex, whereas loss of *Fgfr1* alone is sufficient to result in reduced hippocampal volume and reduced hippocampal stem cell proliferation during embryogenesis and the early postnatal period ([@ref-45]; [@ref-36]; [@ref-59]; [@ref-50]). Our studies of *Fgfr1* expression in embryos and at P1 will be described elsewhere, but support the role of FGFR1 in telencephalic development. At P7, *Fgfr1* was expressed in BLBP positive cells. At this age, the BLBP+ radial glial cells are undergoing soma translocation and differentiating into astrocytes of the cortical parenchyma. FGF signaling may be participating in the soma translocation process, as previously described for the glial cells of the indusium griseum ([@ref-57]), or it may be a general factor expressed by astrocytes since a majority of GFAP+ cells expressed GFP. It is interesting to note that as animals matured from P7 to one-month of age, the relative amount of GFAP/GFP colocalization was increased. This may reflect a maturation of astrocytic glia from BLBP expressing radial glia stem cells undergoing gliogenesis and soma translocation to mature astrocytes that express higher levels of GFAP. BLBP is also expressed in Bergmann glia of the cerebellum, which are cells that have dual roles as stem cells and as a scaffold for granule cell neuron migration and alignment of Purkinje neuron dendrites. The finding that *Fgfr1* is expressed within these cells is consistent with the demonstrated occurrence of cooperative signaling between FGFR1 and FGFR2 in the formation of the cerebellum, and specifically, in the morphology and pial attachment of Bergmann glia of the cerebellar anlage ([@ref-39]; [@ref-43]). FGFR1 may be playing dual roles in these cells as a factor that supports their proliferation, as well as structural morphology, potentially by interactions with cell adhesion molecules ([@ref-72]; [@ref-49]).

At P7, and one month, *Fgfr1* was expressed in the DG and CA regions of the hippocampus, as well as in the SVZ, hypothalamus, and all layers of the cortex. In the DG, expression is primarily found in stem cells as well as DCX positive cells. The *Fgfr1* expressing cells in the CA region at P7 and 1 month colocalize with GFAP positive astrocytes and NeuN positive neurons in the stratum pyramidale. *Fgfr1* expression within GFAP+, and SOX2+ positive cells of the SGZ in the DG indicates that FGFR signaling is contributing to stem cell maintenance and proliferation in the DG, and that alterations in FGFR signaling may contribute to depletion of DG stem cells ([@ref-45]). As reviewed by ([@ref-48]), reduced hippocampal proliferation has been observed in animal models of depression, and antidepressant therapies all promote either hippocampal proliferation or the survival and integration of newborn neurons ([@ref-48]). FGFR signaling also participates in development of hippocampal synaptogenesis ([@ref-10]; [@ref-67]; [@ref-62]). Activation of FGFR1 promotes synapse formation in hippocampal neurons ([@ref-10]; [@ref-62]; [@ref-14]). The expression of *Fgfr1* in DCX positive cells of the hippocampus, as well as neurons in the CA region supports the evidence that FGFR1 plays additional roles in synapse formation and integration into the hippocampal circuitry. These findings have implications for hippocampal function in HPA axis regulation. Changes in *Fgfr1* expression, and FGF2 levels in the hippocampus are linked to major depression and anxiety, as well as to responses to antidepressants ([@ref-18]; [@ref-44]; [@ref-25]; [@ref-64]; [@ref-17]). It is hypothesized that *Fgf2* and *Fgfr1* are downregulated in depression and anxiety, and this downregulation can be partially reversed by antidepressant treatment ([@ref-66]; [@ref-65]). The chronic unpredictable stress model causes anhedonia and is a model of depression that results in decreased (mRNA) *Fgfr1* levels in the prefrontal cortex ([@ref-17]). Antidepressant treatment resulted in increased (mRNA) *Fgf2* levels, and the antidepressant effects could be blocked by an FGFR1 inhibitor. These authors further showed that FGF2 administration also had an antidepressant effect ([@ref-17]). The *tgfgfr1-EGFP*+ mouse line can be utilized to further examine the effects of stress and depression models on *Fgfr1* expression.

GFAP positive astrocytes and BLBP cells in the SVZ at P7 are expressing *GFP*, indicating that stem cells of the SVZ express *Fgfr1*. GFAP positive astrocytes at 1 month also express *Fgfr1*. Our findings in the SVZ are consistent with studies of single cell transcriptomics of the SVZ ([@ref-3]; [@ref-2]; [@ref-40]). For example, molecular studies have identified that CD133+ stem cells of the pallium, capable of generating neurons or glia, have higher levels of *Fgfr1* mRNA compared to other SVZ cell types of the lateral SVZ ([@ref-3]). [@ref-40], identified subpopulations of cells within the SVZ via principle component analysis of co-expressed gene transcripts from single cells, and identified that *Fgfr1* was enriched in Neural Stem Cells (NSCs) that express glial/NSC markers such as *Fabp7* (BLBP), *Slc1a3* (GLAST), *Hes5*, and *Aldh1l1*. *Fgfr1* was co-expressed with Category III cells in that study, which included dynamically regulated genes that change expression as NSC go from a quiescent state to an activated state. Future studies could employ *tgfgfr1-EGFP*+ mice to explore the expression of *Fgfr1* during remyelination and response to injury. *Fgfr1* expressing cells were also colocalized with SOX2 positive cells at 1 month. At P7 and 1 month, *Fgfr1* expressing cells in the SVZ do not colocalize with DCX positive neuroblasts and NeuN positive neurons, as confirmed by single cell transcriptomics studies. Thus, DCX positive cells express *Fgfr1* in one of the postnatal neurogenic regions---the DG. The difference in *Fgfr1* expression observed between DCX positive cells of the DG and SVZ implies that the staining in DCX positive cells of the hippocampus is not due to residual GFP protein that has not been degraded once a daughter cell born from a stem cell stops expressing *Fgfr1*, suggesting we can further accurately identify *Fgfr1* expression within cells using this transgenic model. An alternative explanation is that the lack of DCX in the neurons born from stem cells in the SVZ is that they have a completely different profile and fate (olfactory bulb neurons) compared to the newborn granule neurons of the hippocampus, and thus, would not be expected to express *Fgfr1* in the same way.

Most GFAP positive astrocytes throughout the cortex coexpressed *Fgfr1* at similar levels, and the majority of the *Fgfr1* expressing cells were GFAP+ astrocytes. *Fgfr1* expression seemed to be a general feature of GFAP positive cells and glial stem cells throughout development. A minority of *Fgfr1* expressing cells were NeuN positive neurons at P7 and one month. While it was previously believed that *Fgfr2* is expressed in glia and that *Fgfr1* is mostly expressed by neuronal populations in the adult cortex, our findings support the view that most of the cortical cells expressing *Fgfr1* in the adult brain are, in fact, astrocytes or oligodendrocytes ([@ref-65]). In this study we see that most GFAP positive astrocytes express *Fgfr1* and a small proportion of NeuN positive neurons express *Fgfr1* in one-month old mice. A higher percentage of *Fgfr1* expressing cells are GFAP positive astrocytes rather than NeuN positive neurons. Thus, astrocytes constitute a majority of *Fgfr1* expressing cells in the adult brain. This idea is consistent with previous mRNA profiling of astrocytes in which *Fgfr1* was identified as a gene with enriched expression in astrocytes as compared to other cell types in the brain ([@ref-41]; [@ref-9]; [@ref-15]).

An imbalance of excitatory and inhibitory neurons, along with hyperactivity has been documented in certain neurological disorders ([@ref-6]; [@ref-69]; [@ref-34]; [@ref-1]; [@ref-30]; [@ref-37]; [@ref-28]; [@ref-71]). Inactivation of *Fgfr1* leads to a decrease in the abundance of parvalbumin interneurons in the cortex and is associated with an increase in hyperactivity ([@ref-42]). A subsequent study demonstrated that a decrease in interneurons occurs postnatally and that *Fgfr1* expression does not occur in parvalbumin expressing interneurons ([@ref-56]). Astrocytes lacking *Fgfr1* were less capable of supporting the maturation of *Gad67* expressing cells than control astrocytes. Here, we find that *Fgfr1* is expressed by a majority of astrocytes in the cortex and hippocampus throughout the maturational period of parvalbumin positive interneurons, further supporting the importance for FGFR1 signaling in astrocytes. Current studies are seeking to explore how FGFR1 signaling within astrocytes contributes to interneuron maturation.

Here, we tested other interneuron markers, including GAD67, calretinin, and somatostatin. At one month, GAD67, a marker for inhibitory neurons, colocalizes with *Fgfr1* expressing cells in the cortex and not in the DG. Calretinin interneurons express *Fgfr1* throughout the cortex, and in the DG, whereas somatostatin interneurons express *Fgfr1* at the anterior cingulate of the cortex. [@ref-8] demonstrated newborn calretinin positive cells in the DG do not express GABA, offering a probable explanation as to why GAD67 is not observed colocalizing with *Fgfr1* expressing cells in the DG.

The hypothalamus, responsible for controlling hormonal production, stress regulation, and feeding behaviors, has been found to contain a neural stem/progenitor cell niche ([@ref-52]). Our results show that GFAP positive astrocytes are *Fgfr1* expressing cells. The morphology and location of the *Fgfr1* expressing cells are consistent with the cells being tanycytes of the hypothalamus ([@ref-52]). The median eminence of the hypothalamus contains *Fgfr1* expressing cells that also express SOX2. *Fgfr1* expressing cells that were not identified are similar in morphology and location to the neurons that release gonadotropin-releasing hormone (GNRH1). These results are in congruence with a study, which demonstrated FGFR1's role in the targeting of GNRH1 axons to the median eminence ([@ref-26]; [@ref-46]). Therefore, understanding FGFR signaling can give further insight to the hypothalamic regulation of homeostasis.
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###### Qualitative comparison of *Fgfr1* expression

![](peerj-05-3173-g013)

  Time point   Area           *Fgfr1* expression in cell types                              
  ------------ -------------- ---------------------------------- ----- ----- -------- ----- -----
  P7           DG             + +                                + +   NA    + +  +   \+    
               CA                                                + +   NA             + +   
               SVZ            + +  +                             \+    NA                   + +
               Cortex         + +  +                             + +   NA             \+    + +
               Hypothalamus                                      + +   NA                   
  1 month      DG                                                + +   + +   + +            
               CA                                                \+                   \+    
               SVZ                                               + +   + +                  
               Cortex                                            + +                  \+    \+
               Hypothalamus                                      + +   + +                  

**Notes.**

NAnot analyzed

Conclusion
==========

FGFR1 has been implicated as having multiple functions in CNS development, homeostasis, and behavior, but defining the cellular basis of its functions depends on having a clear understanding of which cell types the *Fgfr1* gene is expressed in, and when. The GENSAT project was envisioned as a resource that would provide the tools for such detailed studies ([@ref-32]). Here, we have extended the previously published *in situ* based studies and online resources with a detailed examination of the *tgFGR1-EGFPGP338Gsat* line. Our data are congruent with *in situ* studies, but with the added feature of double immunofluorescence with glial and neuronal markers, and a quantification of the relative expression in glial versus neuronal cells in the young adult brain. We here find *Fgfr1* promoter driven GFP expression in a variety of stem cells of the CNS including the young adult SVZ, young adult SGZ, cerebellar Bergmann Glia, and SOX2+ cells of the hypothalamus (summarized in [Table 4](#table-4){ref-type="table"}). An additional study of *Fgfr1* expression in embryonic and perinatal stem cells will be described elsewhere. We also find that *Fgfr1* is expressed predominantly in glia in the young adult brain, although significant expression in DCX+ positive neuroblasts of the hippocampus was also observed. This was in stark contrast to DCX+ neuroblasts of the RMS. Our findings may shed light on the participation of FGF2/FGFR1 signaling in determining anxiety and mood, where a neuronal role for FGFR1 has been hypothesized ([@ref-65]). Future studies are needed to determine whether *Fgfr1* expression colocalizes with other markers, such as S100β, O4, and NG2 at embryonic and postnatal time points. Since *Gfap* is not expressed in all astrocytes, S100β (glial specific marker primarily expressed in astrocytes, but also in some ependymal cells) would be a good marker to further explore *Fgfr1* expression. The *tgFgfr1-EGFP*+ model can also be used to study additional stages in development, or *Fgfr1* expression after environmental manipulations previously shown to alter *Fgfr1* expression, including animal models for induced depression such as social defeat stress.
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###### *Fgfr1* and GFAP expression in the DG and CA regions of the hippocampus of P7 mice

GFAP (red), and GFP immunostaining of the DG in P7 *tgfgfr1-EGFP*+ mice (A--C, and G--I, *n* = 3) and *tgfgfr1-EGFP-*controls (D--F, and **J**-**L**, *n* = 3). Comparison of the DG of the Hippocampus (A--C and D--F), and CA regions (G--I and J--L) revealed GFP+ staining in GFAP+ cells in the SGZ of the DG and in the CA region (D), as well as in white matter. DAPI, Blue channel. Dashed line indicates outer hippocampus/white matter boundary. Scale bars are 50 µm.

###### 

Click here for additional data file.
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###### *Fgfr1* and NeuN expression in CA region of the hippocampus P7 mice

NeuN (A, D) and GFP (B, E) immunostaining of the CA region in *tgfgfr1-EGFP*+ mice (A--C, *n* = 3) and tgfgfr1-EGFP- controls (D--F, *n* = 3). Neun+/GFP+ staining was observed in stratum pyramidale (SP) of the CA region. Dashed line indicated outer hippocampus/white matter boundary. Scale bars are 50 µm.

###### 

Click here for additional data file.
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###### NeuN and GFAP staining in the cerebellum of *tgfr1-EGFP*+ mice at P7

NeuN+ granule cell layer neurons did not colocalize with GFP at P7 (A, low magnification, B, high magnification). GFAP+ glia of the cerebellum do colocalize with GFP at P7 (C, low magnification, D, high magnification). Arrow heads denote double labeled cells while small arrows denote GFAP+/GFP+ glial fibers. Scale bar is 50 µm in A, C, and 25 µm in B, D.

###### 

Click here for additional data file.
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###### *FGFR1* expression in the hippocampus at 1 Month in *tgfgfr1-EGFP*+ mice

Low magnification images of SOX2 (A) and SOX2/GFP colabeling (B) in the DG of *tgfgfr1-EGFP*+ mice. Low magnification images of DCX (C) and DCX/GFP colabeling (D) in the DG of *tgfgfr1-EGFP*+ mice. High Magnification images of GFAP (red)/NeuN (blue)/GFP triple staining in the DG (E) and CA (F). Scale bar is 50 µm in A--D, and 25 µm in (E-F).

###### 

Click here for additional data file.
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###### *Fgfr1* promoter driven GFP does not colocalize with Olig2+ cells in the hippocampus

OLIG2 staining in the hippocampus of control *tgfgfr1-EGFP-*mice (A--D) and *tgfgfr1-EGFP*+ mice (E--H). Scale bar is 50 µm.

###### 

Click here for additional data file.
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###### *FGFR1* expression in the hypothalamus

*Fgfr1* promoter driven GFP in the hypothalamus of control *tgfgfr1-EGFP-*mice (A, B) and *tgfgfr1-EGFP*+ mice (C--F). OLIG2+ cells in the hypothalamus do not colocalize with *Fgfr1* promoter driven GFP+ (C, D). BLBP+ cells near the third ventricle do colocolize with *Fgfr1* promoter driven GFP (E), but do not colocalize with GFP in the medial eminence (F). Scale bar is 50 µm in A, C, E and 25 µm in B, D, F.

###### 

Click here for additional data file.
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